Most Recent Articles by Laura Entis
AI's marketing problem: Inflated claims, outsized expectations may actually be slowing AI's move into clinical practiceMar 21, 2018
The potential is real, but companies and technology gurus often speak of machine learning as a catch-all solution. The hype may be slowing AI's incremental growth in healthcare, experts say.
Roche's immunotherapy Tecentriq, when combined with a Abraxane-based chemo, decreased the risk of disease worsening or death compared to chemo alone in first-line patients with advanced squamous non-small cell lung cancer; President Trump spoke about using federal prosecutors to sue opioid makers; Trump also vowed to bring down the cost of prescription drugs.
Congress has spent less than a quarter of the $500 million to fight the opioid epidemic; The #MeToo movement is gaining steam in the medical industry; Dr. Robert R. Redfield, a leading AIDS researcher, is the top candidate to lead the Centers for Disease Control and Prevention.
How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
MM&M spoke with Gazzaley about what's next for Akili, how he defines "digital medicine," and where the field is currently positioned on the hype cycle.